Compare Sana Biotechnology Inc (SANA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Vanguard Total International Stock Index Fund ETF trades at $87.91. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VXUS | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $88.41 |
52-Week Low | $2.68 | $72.17 |
Enterprise Value | $946.04M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VXUS trades at $88.08, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF offers broad international stock exposure, excluding U.S. equities, with a low expense ratio of 0.06% as of Vanguard's latest disclosure in 2026. Recent news highlights institutional buying and long-term growth potential amid U.S. market concentration concerns.
Outlook is positive for diversification benefits and valuation discounts relative to U.S. stocks, supported by analyst optimism. Risks include foreign tax credit limitations in IRAs and emerging market volatility. Wall Street sentiment leans bullish due to improved global growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
